See the DrugPatentWatch profile for vyvanse

Based on the information available, I was unable to find specific data comparing the exact prices of brand-name Vyvanse and its generic versions. However, I can provide some context that will help you understand how much generic versions might cost compared to the brand-name drug.

Generic drugs are typically less expensive than their brand-name counterparts due to reduced research, development, and marketing costs [1]. Once a drug's patent expires, other manufacturers can produce generic versions, leading to increased competition and lower prices [1].

Vyvanse (lisdexamfetamine dimesylate) is a prescription medication used to treat attention deficit hyperactivity disorder (ADHD) and moderate-to-severe binge eating disorder [2]. Vyvanse's patent expired in August 2020 [3], allowing other manufacturers to produce generic versions.

According to DrugPatentWatch.com, the first generic version of Vyvanse was approved by the FDA in December 2020 [3]. As a result, you can expect generic versions of Vyvanse to become available in the US market soon, if they aren't already [3].

While I cannot provide an exact percentage or dollar amount for the price difference between brand-name Vyvanse and its generic versions, you can generally expect generic drugs to cost 80-85% less than their brand-name counterparts [1].

In summary, generic versions of Vyvanse are expected to be significantly cheaper than the brand-name drug, although the exact price difference is not available.

Sources:
[1] <https://www.fda.gov/drugs/understanding-generic-drugs>
[2] <https://www.vyvanse.com/about-vyvanse/what-is-vyvanse>
[3] <https://www.drugpatentwatch.com/drugs/vyvanse>